A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer.

Taiki Hashimoto Daisuke TakayanagiJunpei YonemaruTomoaki NakaKengo NagashimaErika MachidaTakashi KohnoYasushi YatabeYukihide KanemitsuRyuji Hamamoto Atsuo Takashima Kouya Shiraishi Shigeki Sekine

Published in: British journal of cancer (2023)

These results suggest that biopsy-based assessment of primary lesions is appropriate for the identification of CRC patients eligible for systemic HER2-targeted therapy.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
bioinformatics analysis